Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome (BIOMINRISK)
Risk Stratification of Sudden Unexpected Death in Infant Based on Biomarkers - Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome
Sponsor: AXA Assurances VIE Mutuelle
Listed as NCT06244433, this observational or N/A phase trial focuses on Sudden Infant Death and Sudden Unexplained Infant Death and remains actively recruiting participants. Sponsored by AXA Assurances VIE Mutuelle, it has been updated 6 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Recruiting
-
Feb 2025 — Sep 2025 [monthly]
Recruiting
-
Oct 2024 — Feb 2025 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
▶ Show 1 earlier version
-
Mar 2024 — Jul 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AXA Assurances VIE Mutuelle
- Institut du Thorax
- Nantes University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Angers, France , Besançon, France , Bondy, France , Brest, France , Clamart, France , Grenoble, France , Lyon, France , Marseille, France , Montpellier, France and 5 more locations